PolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II Trial

PolyPid ( (PYPD) ) has shared an announcement.

On June 9, 2025, PolyPid Ltd. announced positive topline results from its Phase 3 SHIELD II trial, demonstrating that D-PLEX100 significantly reduces surgical site infections (SSIs) in patients undergoing large abdominal surgeries. The trial met its primary and all key secondary endpoints, showing a 58% reduction in SSI rates compared to the standard of care. With these results, PolyPid plans to submit a New Drug Application to the FDA in early 2026, targeting a substantial U.S. market of over 12 million annual surgeries. The successful trial outcomes are expected to advance global partnership discussions and potentially lower healthcare costs, positioning D-PLEX100 as a valuable addition to surgical care.

The most recent analyst rating on (PYPD) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.

Spark’s Take on PYPD Stock

According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.

PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.

To see Spark’s full report on PYPD stock, click here.

More about PolyPid

PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This technology enables the precise delivery of drugs at optimal release rates over extended durations. PolyPid’s lead product candidate, D-PLEX100, is in a Phase 3 clinical trial aimed at preventing abdominal colorectal surgical site infections.

Average Trading Volume: 33,356

Technical Sentiment Signal: Sell

Current Market Cap: $33.32M

Learn more about PYPD stock on TipRanks’ Stock Analysis page.